Stratus Versus Cirrus OCT in AMD

This study is currently recruiting participants.

Verified by The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery, December 2007

First Received: December 4, 2007 No Changes Posted

Sponsored by:	The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Information provided by:	The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
ClinicalTrials.gov Identifier:	NCT00568191

Purpose

The Cirrus OCT provides due to the spectral domain technology a 2-fold resolution than Stratus OCT generated in a comparable amount of time. Due to this higher resolution the retinal surface and the retinal pigment epithelium can be identified more clearly, a significantly reduced number of algorithm failures is expected

Condition
Age-Related Macular Degeneration Choroidal Neovascularization

Genetics Home Reference related topics: X-linked juvenile retinoschisis

MedlinePlus related topics: Macular Degeneration

U.S. FDA Resources

Study Type:	Observational
Study Design:	Case-Only, Prospective
Official Title:	Reliability of Threshold Algorithm in Age-Related Macular Degeneration: Stratus Versus Cirrus OCT

Further study details as provided by The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery:

Primary Outcome Measures:

Number of algorithm failures assessed by Stratus OCT versus Cirrus OCT in the horizontal central line [ Time Frame: only 1 examination ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Number of algorrithm failures in Stratus versus Cirrus OCT assessed in the whole scan [ Time Frame: 1 examination ] [ Designated as safety issue: No ]

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	100
Study Start Date:	October 2007
Estimated Study Completion Date:	December 2007

Groups/Cohorts
1 retinal thickness program Stratus OCT software 4.0
2 retinal cube 200x200 program of Cirrus OCT

Eligibility

Ages Eligible for Study:	55 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Patients aged > 55 years of either sex presenting with age-related macular degeneration

Criteria

Inclusion Criteria:

Age>55 years
Age-related macular degeneration

Exclusion Criteria:

Not consented patients

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00568191

Contacts

Contact: Ilse Krebs, MD

+43171165 ext 94607

Ilse.Krebs@wienkav.at

Locations

Austria
Ludwig Boltzmann Institute for Retinology and Biomicroscopic Lasersurgery	Recruiting
Vienna, Austria, A1030
Contact: Ilse Krebs, MD +43171165 ext 4607 Ilse.Krebs@wienkav.at
Principal Investigator: Ilse Krebs, MD

Sponsors and Collaborators

The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery

Investigators

Principal Investigator:

Ilse Krebs

Ludwig Boltzmann Institute of Retinology and Biomicroscopic Lasersurgery

More Information

No publications provided by The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery

Additional publications automatically indexed to this study by National Clinical Trials Identifier (NCT ID):

Krebs I, Falkner-Radler C, Hagen S, Haas P, Brannath W, Lie S, Ansari-Shahrezaei S, Binder S. Quality of the threshold algorithm in age-related macular degeneration: Stratus versus Cirrus OCT. Invest Ophthalmol Vis Sci. 2009 Mar;50(3):995-1000. Epub 2008 Nov 21.

Responsible Party:	The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery ( Prof Susanne Binder )
Study ID Numbers:	EK 06-007-VK1
Study First Received:	December 4, 2007
Last Updated:	December 4, 2007
ClinicalTrials.gov Identifier:	NCT00568191 History of Changes
Health Authority:	Austria: Ethikkommission

Keywords provided by The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery:

Age-related macular degeneration
choroidal neovascularization
Stratus OCT
Cirrus OCT

Study placed in the following topic categories:

Metaplasia
Eye Diseases
Choroid Diseases
Retinal Degeneration

Macular Degeneration
Neovascularization, Pathologic
Retinal Diseases
Choroidal Neovascularization

Additional relevant MeSH terms:

Uveal Diseases
Pathologic Processes
Metaplasia
Eye Diseases
Choroid Diseases

Retinal Degeneration
Macular Degeneration
Neovascularization, Pathologic
Retinal Diseases
Choroidal Neovascularization

ClinicalTrials.gov processed this record on May 06, 2009